11β-Hydroxysteroid dehydrogenase 1: Regeneration of active glucocorticoids is only part of the story

Journal of Steroid Biochemistry and Molecular Biology

Volumn 151, Issue , 2015, Pages 85-92

  Odermatt, Alex ^a   Klusonova, Petra ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

11 Hydroxysteroid dehydrogenase; Bile acid; Carbonyl reduction; Cholesterol; Glucocorticoid; Metabolism; Xenobiotic

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 7-KETOCHOLESTEROL; BILE ACID; CHOLESTEROL DERIVATIVE; GLUCOCORTICOID;

ANIMAL; ATHEROSCLEROSIS; HUMAN; METABOLISM;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; GLUCOCORTICOIDS; HUMANS; KETOCHOLESTEROLS;

EID: 85028217080     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2014.08.011     Document Type: Review

References (102)

1. Barnes, P.J., Glucocorticosteroids: current and future directions. Br. J. Pharmacol. 163 (2011), 29–43.
2. Kadmiel, M., Cidlowski, J.A., Glucocorticoid receptor signaling in health and disease. Trends Pharmacol. Sci. 34 (2013), 518–530.
3. Singh, R.R., Cuffe, J.S., Moritz, K.M., Short- and long-term effects of exposure to natural and synthetic glucocorticoids during development. Clin. Exp. Pharmacol. Physiol. 39 (2012), 979–989.
4. Bergmann, T.K., Barraclough, K.A., Lee, K.J., Staatz, C.E., Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Clin. Pharmacokinet. 51 (2012), 711–741.
5. Odermatt, A., Kratschmar, D.V., Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: an overview. Mol. Cell. Endocrinol. 350 (2012), 168–186.
6. Amelung, D., Hubener, H.J., Roka, L., Meyerheim, G., Conversion of cortisone to compound F. J. Clin. Endocrinol. Metab. 13 (1953), 1125–1126.
7. Monder, C., Lakshmi, V., Corticosteroid 11β-hydroxysteroid dehydrogenase activities in vertebrate liver. Steroids 52 (1988), 515–528.
8. Agarwal, A.K., Monder, C., Eckstein, B., White, P.C., Cloning and expression of rat cDNA encoding corticosteroid 11β-dehydrogenase. J. Biol. Chem. 264 (1989), 18939–18943.
9. Agarwal, A.K., Tusie-Luna, M.T., Monder, C., White, P.C., Expression of 11β-hydroxysteroid dehydrogenase using recombinant vaccinia virus. Mol. Endocrinol. 4 (1990), 1827–1832.
10. Low, S.C., Assaad, S.N., Rajan, V., Chapman, K.E., Edwards, C.R., Seckl, J.R., Regulation of 11β-hydroxysteroid dehydrogenase by sex steroids in vivo: further evidence for the existence of a second dehydrogenase in rat kidney. J. Endocrinol. 139 (1993), 27–35.
11. Mziaut, H., Korza, G., Hand, A.R., Gerard, C., Ozols, J., Targeting proteins to the lumen of endoplasmic reticulum using N-terminal domains of 11β-hydroxysteroid dehydrogenase and the 50 kDa esterase. J. Biol. Chem. 274 (1999), 14122–14129.
12. Odermatt, A., Arnold, P., Stauffer, A., Frey, B.M., Frey, F.J., The N-terminal anchor sequences of 11β-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J. Biol. Chem. 274 (1999), 28762–28770.
13. Ozols, J., Lumenal orientation and post-translational modifications of the liver microsomal 11β-hydroxysteroid dehydrogenase. J. Biol. Chem. 270 (1995), 2305–2312.
14. Atanasov, A.G., Nashev, L.G., Schweizer, R.A., Frick, C., Odermatt, A., Hexose-6-phosphate dehydrogenase determines the reaction direction of 11β-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Lett. 571 (2004), 129–133.
15. Banhegyi, G., Benedetti, A., Fulceri, R., Senesi, S., Cooperativity between 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the lumen of the endoplasmic reticulum. J. Biol. Chem. 279 (2004), 27017–27021.
16. Beutler, E., Morrison, M., Localization and characteristics of hexose 6-phosphate dehydrogenase (glucose dehydrogenase). J. Biol. Chem. 242 (1967), 5289–5293.
17. Romanelli, A., St-Denis, J.F., Vidal, H., Tchu, S., van de Werve, G., Absence of glucose uptake by liver microsomes: an explanation for the complete latency of glucose dehydrogenase. Biochem. Biophys. Res. Commun. 200 (1994), 1491–1497.
18. Kulkarni, A.P., Hodgson, E., Mouse liver microsomal hexose-6-phosphate dehydrogenase. NADPH generation and utilization in monooxygenation reactions. Biochem. Pharmacol. 31 (1982), 1131–1137.
19. Mason, P.J., Stevens, D., Diez, A., Knight, S.W., Scopes, D.A., Vulliamy, T.J., Human hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) encoded at 1p36: coding sequence and expression. Blood Cells Mol. Dis. 25 (1999), 30–37.
20. Chou, J.Y., Mansfield, B.C., The SLC37 family of sugar-phosphate/phosphate exchangers. Curr. Top. Membr. 73 (2014), 357–382.
21. Dzyakanchuk, A.A., Balazs, Z., Nashev, L.G., Amrein, K.E., Odermatt, A., 11β-Hydroxysteroid dehydrogenase 1 reductase activity is dependent on a high ratio of NADPH/NADP(+) and is stimulated by extracellular glucose. Mol. Cell. Endocrinol. 301 (2009), 137–141.
22. Atanasov, A.G., Nashev, L.G., Gelman, L., Legeza, B., Sack, R., Portmann, R., Odermatt, A., Direct protein–protein interaction of 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the endoplasmic reticulum lumen. Biochim. Biophys. Acta 1783 (2008), 1536–1543.
23. Zhang, Y.L., Zhong, X., Gjoka, Z., Li, Y., Stochaj, W., Stahl, M., Kriz, R., Tobin, J.F., Erbe, D., Suri, V., H6PDH interacts directly with 11β-HSD1: implications for determining the directionality of glucocorticoid catalysis. Arch. Biochem. Biophys. 483 (2009), 45–54.
24. Gomez-Sanchez, E.P., Romero, D.G., de Rodriguez, A.F., Warden, M.P., Krozowski, Z., Gomez-Sanchez, C.E., Hexose-6-phosphate dehydrogenase and 11β-hydroxysteroid dehydrogenase-1 tissue distribution in the rat. Endocrinology 149 (2008), 525–533.
25. Furstenberger, C., Vuorinen, A., Da Cunha, T., Kratschmar, D.V., Saugy, M., Schuster, D., Odermatt, A., The anabolic androgenic steroid fluoxymesterone inhibits 11β-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation. Toxicol. Sci. 126 (2012), 353–361.
26. Rebuffat, A.G., Tam, S., Nawrocki, A.R., Baker, M.E., Frey, B.M., Frey, F.J., Odermatt, A., The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist. Mol. Cell. Endocrinol. 214 (2004), 27–37.
27. Diederich, S., Hanke, B., Oelkers, W., Bahr, V., Metabolism of dexamethasone in the human kidney: nicotinamide adenine dinucleotide-dependent 11β-reduction. J. Clin. Endocrinol. Metab. 82 (1997), 1598–1602.
28. Diederich, S., Eigendorff, E., Burkhardt, P., Quinkler, M., Bumke-Vogt, C., Rochel, M., Seidelmann, D., Esperling, P., Oelkers, W., Bahr, V., 11β-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J. Clin. Endocrinol. Metab. 87 (2002), 5695–5701.
29. Feldman, B.J., Is your metabolism determined by (cell) fate?. Pediatr. Res. 61 (2007), 636–639.
30. Bujalska, I.J., Kumar, S., Stewart, P.M., Does central obesity reflect Cushing's disease of the omentum?. Lancet 349 (1997), 1210–1213.
31. Stewart, P.M., Tissue-specific Cushing's syndrome, 11β-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur. J. Endocrinol. 149 (2003), 163–168.
32. Paterson, J.M., Seckl, J.R., Mullins, J.J., Genetic manipulation of 11β-hydroxysteroid dehydrogenases in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289 (2005), R642–652.
33. Gathercole, L.L., Lavery, G.G., Morgan, S.A., Cooper, M.S., Sinclair, A.J., Tomlinson, J.W., Stewart, P.M., 11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocr. Rev. 34 (2013), 525–555.
34. Kotelevtsev, Y., Holmes, M.C., Burchell, A., Houston, P.M., Schmoll, D., Jamieson, P., Best, R., Brown, R., Edwards, C.R., Seckl, J.R., Mullins, J.J., 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 14924–14929.
35. Morton, N.M., Holmes, M.C., Fievet, C., Staels, B., Tailleux, A., Mullins, J.J., Seckl, J.R., Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276 (2001), 41293–41300.
36. Morton, N.M., Paterson, J.M., Masuzaki, H., Holmes, M.C., Staels, B., Fievet, C., Walker, B.R., Flier, J.S., Mullins, J.J., Seckl, J.R., Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53 (2004), 931–938.
37. Harno, E., Cottrell, E.C., Yu, A., DeSchoolmeester, J., Gutierrez, P.M., Denn, M., Swales, J.G., Goldberg, F.W., Bohlooly, Y.M., Andersen, H., Wild, M.J., Turnbull, A.V., Leighton, B., White, A., 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors still improve metabolic phenotype in male 11β-HSD1 knockout mice suggesting off-target mechanisms. Endocrinology 154 (2013), 4580–4593.
38. Masuzaki, H., Paterson, J., Shinyama, H., Morton, N.M., Mullins, J.J., Seckl, J.R., Flier, J.S., A transgenic model of visceral obesity and the metabolic syndrome. Science 294 (2001), 2166–2170.
39. Masuzaki, H., Yamamoto, H., Kenyon, C.J., Elmquist, J.K., Morton, N.M., Paterson, J.M., Shinyama, H., Sharp, M.G., Fleming, S., Mullins, J.J., Seckl, J.R., Flier, J.S., Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Investig. 112 (2003), 83–90.
40. Paterson, J.M., Morton, N.M., Fievet, C., Kenyon, C.J., Holmes, M.C., Staels, B., Seckl, J.R., Mullins, J.J., Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 7088–7093.
41. Rosenstock, J., Banarer, S., Fonseca, V.A., Inzucchi, S.E., Sun, W., Yao, W., Hollis, G., Flores, R., Levy, R., Williams, W.V., Seckl, J.R., Huber, R., The 11β-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33 (2010), 1516–1522.
42. Scott, J.S., Goldberg, F.W., Turnbull, A.V., Medicinal chemistry of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). J. Med. Chem. 57 (2014), 4466–4486.
43. Lavery, G.G., Zielinska, A.E., Gathercole, L.L., Hughes, B., Semjonous, N., Guest, P., Saqib, K., Sherlock, M., Reynolds, G., Morgan, S.A., Tomlinson, J.W., Walker, E.A., Rabbitt, E.H., Stewart, P.M., Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology 153 (2012), 3236–3248.
44. Penno, C.A., Morgan, S.A., Rose, A.J., Herzig, S., Lavery, G.G., Odermatt, A., 11β-Hydroxysteroid dehydrogenase-1 is involved in bile acid homeostasis by modulating fatty acid transport protein-5 in the liver of mice. Mol. Metab. 3 (2014), 554–564.
45. Odermatt, A., Atanasov, A.G., Balazs, Z., Schweizer, R.A., Nashev, L.G., Schuster, D., Langer, T., Why is 11β-hydroxysteroid dehydrogenase type 1 facing the endoplasmic reticulum lumen? Physiological relevance of the membrane topology of 11β-HSD1. Mol. Cell. Endocrinol. 248 (2006), 15–23.
46. Odermatt, A., Nashev, L.G., The glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: physiological and toxicological considerations. J. Steroid Biochem. Mol. Biol. 119 (2010), 1–13.
47. Burton, G., Galigniana, M., De Lavallaz, S., Brachet-Cota, A.L., Sproviero, E.M., Ghini, A.A., Lantos, C.P., Damasco, M.C., Sodium-retaining activity of some natural and synthetic 21-deoxysteroids. Mol. Pharmacol. 47 (1995), 535–543.
48. Galigniana, M.D., Vicent, G.P., Burton, G., Lantos, C.P., Features of the shuttle pair 11β-hydroxyprogesterone-11-ketoprogesterone. Steroids 62 (1997), 358–364.
49. Axelrod, L.R., Kraemer, D.C., Burdett, J. Jr., Goldzieher, J.W., Biosynthesis of 11-hydroxyandrostenedione by human and baboon adrenals. Acta Endocrinol. (Copenh.) 72 (1973), 545–550.
50. Rege, J., Nakamura, Y., Satoh, F., Morimoto, R., Kennedy, M.R., Layman, L.C., Honma, S., Sasano, H., Rainey, W.E., Liquid chromatography–tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation. J. Clin. Endocrinol. Metab. 98 (2013), 1182–1188.
51. Swart, A.C., Schloms, L., Storbeck, K.H., Bloem, L.M., Toit, T., Quanson, J.L., Rainey, W.E., Swart, P., 11β-hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione. J. Steroid Biochem. Mol. Biol. 138 (2013), 132–142.
52. Storbeck, K.H., Bloem, L.M., Africander, D., Schloms, L., Swart, P., Swart, A.C., 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?. Mol. Cell. Endocrinol. 377 (2013), 135–146.
53. Lathe, R., Steroid and sterol 7-hydroxylation: ancient pathways. Steroids 67 (2002), 967–977.
54. Lathe, R., Kotelevtsev, Y., Steroid signaling: ligand-binding promiscuity, molecular symmetry, and the need for gating. Steroids 82 (2014), 14–22.
55. Robinzon, B., Michael, K.K., Ripp, S.L., Winters, S.J., Prough, R.A., Glucocorticoids inhibit interconversion of 7-hydroxy and 7-oxo metabolites of dehydroepiandrosterone: a role for 11β-hydroxysteroid dehydrogenases?. Arch. Biochem. Biophys. 412 (2003), 251–258.
56. Robinzon, B., Prough, R.A., Interactions between dehydroepiandrosterone and glucocorticoid metabolism in pig kidney: nuclear and microsomal 11β-hydroxysteroid dehydrogenases. Arch. Biochem. Biophys. 442 (2005), 33–40.
57. Muller, C., Pompon, D., Urban, P., Morfin, R., Inter-conversion of 7α- and 7β-hydroxy-dehydroepiandrosterone by the human 11β-hydroxysteroid dehydrogenase type 1. J. Steroid Biochem. Mol. Biol. 99 (2006), 215–222.
58. Nashev, L.G., Chandsawangbhuwana, C., Balazs, Z., Atanasov, A.G., Dick, B., Frey, F.J., Baker, M.E., Odermatt, A., Hexose-6-phosphate dehydrogenase modulates 11β-hydroxysteroid dehydrogenase type 1-dependent metabolism of 7-keto- and 7β-hydroxy-neurosteroids. PLoS One, 2, 2007, e561.
59. Hu, G.X., Lian, Q.Q., Chen, B.B., Prasad, P.V., Kumar, N., Zheng, Z.Q., Ge, R.S., 7α-hydroxytestosterone affects 11β-hydroxysteroid dehydrogenase 1 direction in rat Leydig cells. Endocrinology 151 (2010), 748–754.
60. Muller, C., Hennebert, O., Morfin, R., The native anti-glucocorticoid paradigm. J. Steroid Biochem. Mol. Biol. 100 (2006), 95–105.
61. Gottfried-Blackmore, A., Jellinck, P.H., Vecchiarelli, H.A., Masheeb, Z., Kaufmann, M., McEwen, B.S., Bulloch, K., 7α-hydroxylation of dehydroepiandrosterone does not interfere with the activation of glucocorticoids by 11β-hydroxysteroid dehydrogenase in E(t)C cerebellar neurons. J. Steroid Biochem. Mol. Biol. 138 (2013), 290–297.
62. Balazs, Z., Nashev, L.G., Chandsawangbhuwana, C., Baker, M.E., Odermatt, A., Hexose-6-phosphate dehydrogenase modulates the effect of inhibitors and alternative substrates of 11β-hydroxysteroid dehydrogenase 1. Mol. Cell. Endocrinol. 301 (2009), 117–122.
63. Balazs, Z., Schweizer, R.A., Frey, F.J., Rohner-Jeanrenaud, F., Odermatt, A., DHEA induces 11β-HSD2 by acting on CCAAT/enhancer-binding proteins. J. Am. Soc. Nephrol. 19 (2008), 92–101.
64. Apostolova, G., Schweizer, R.A., Balazs, Z., Kostadinova, R.M., Odermatt, A., Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am. J. Physiol. Endocrinol. Metab. 288 (2005), E957–964.
65. McNelis, J.C., Manolopoulos, K.N., Gathercole, L.L., Bujalska, I.J., Stewart, P.M., Tomlinson, J.W., Arlt, W., Dehydroepiandrosterone exerts antiglucocorticoid action on human preadipocyte proliferation, differentiation, and glucose uptake. Am. J. Physiol. Endocrinol. Metab. 305 (2013), E1134–1144.
66. Odermatt, A., Da Cunha, T., Penno, C.A., Chandsawangbhuwana, C., Reichert, C., Wolf, A., Dong, M., Baker, M.E., Hepatic reduction of the secondary bile acid 7-oxolithocholic acid is mediated by 11β-hydroxysteroid dehydrogenase 1. Biochem. J. 436 (2011), 621–629.
67. Ridlon, J.M., Kang, D.J., Hylemon, P.B., Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47 (2006), 241–259.
68. Fromm, H., Carlson, G.L., Hofmann, A.F., Farivar, S., Amin, P., Metabolism in man of 7-ketolithocholic acid: precursor of cheno- and ursodeoxycholic acids. Am. J. Physiol. 239 (1980), G161–166.
69. Fromm, H., Sarva, R.P., Bazzoli, F., Formation of ursodeoxycholic acid from chenodeoxycholic acid in the human colon: studies of the role of 7-ketolithocholic acid as an intermediate. J. Lipid Res. 24 (1983), 841–853.
70. Salen, G., Verga, D., Batta, A.K., Tint, G.S., Shefer, S., Effect of 7-ketolithocholic acid on bile acid metabolism in humans. Gastroenterology 83 (1982), 341–347.
71. Amuro, Y., Yamade, W., Kudo, K., Yamamoto, T., Hada, T., Higashino, K., Reduction of 7-ketolithocholic acid by human liver enzyme preparations in vitro. Am. J. Physiol. 256 (1989), G67–71.
72. Amuro, Y., Yamade, W., Nakano, T., Hayashi, E., Hada, T., Higashino, K., Reduction of 7-ketolithocholic acid to chenodeoxycholic acid by rat liver preparations in vitro. Biochim. Biophys. Acta 841 (1985), 229–231.
73. Penno, C.A., Morgan, S.A., Vuorinen, A., Schuster, D., Lavery, G.G., Odermatt, A., Impaired oxidoreduction by 11β-hydroxysteroid dehydrogenase 1 results in the accumulation of 7-oxolithocholic acid. J. Lipid Res. 54 (2013), 2874–2883.
74. Trauner, M., Claudel, T., Fickert, P., Moustafa, T., Wagner, M., Bile acids as regulators of hepatic lipid and glucose metabolism. Dig. Dis. 28 (2010), 220–224.
75. Song, W., Chen, J., Dean, W.L., Redinger, R.N., Prough, R.A., Purification and characterization of hamster liver microsomal 7α-hydroxycholesterol dehydrogenase. Similarity to type I 11β-hydroxysteroid dehydrogenase. J. Biol. Chem. 273 (1998), 16223–16228.
76. Schweizer, R.A., Zurcher, M., Balazs, Z., Dick, B., Odermatt, A., Rapid hepatic metabolism of 7-ketocholesterol by 11β-hydroxysteroid dehydrogenase type 1: species-specific differences between the rat, human, and hamster enzyme. J. Biol. Chem. 279 (2004), 18415–18424.
77. Hult, M., Elleby, B., Shafqat, N., Svensson, S., Rane, A., Jornvall, H., Abrahmsen, L., Oppermann, U., Human and rodent type 1 11β-hydroxysteroid dehydrogenases are 7β-hydroxycholesterol dehydrogenases involved in oxysterol metabolism. Cell. Mol. Life Sci. 61 (2004), 992–999.
78. Arampatzis, S., Kadereit, B., Schuster, D., Balazs, Z., Schweizer, R.A., Frey, F.J., Langer, T., Odermatt, A., Comparative enzymology of 11β-hydroxysteroid dehydrogenase type 1 from six species. J. Mol. Endocrinol. 35 (2005), 89–101.
79. Mitic, T., Shave, S., Semjonous, N., McNae, I., Cobice, D.F., Lavery, G.G., Webster, S.P., Hadoke, P.W., Walker, B.R., Andrew, R., 11β-Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxy-oxysterols in vivo. Biochem. Pharmacol. 86 (2013), 146–153.
80. Mitic, T., Andrew, R., Walker, B.R., Hadoke, P.W., 11β-Hydroxysteroid dehydrogenase type 1 contributes to the regulation of 7-oxysterol levels in the arterial wall through the inter-conversion of 7-ketocholesterol and 7β-hydroxycholesterol. Biochimie 95 (2013), 548–555.
81. Moore, K.J., Tabas, I., Macrophages in the pathogenesis of atherosclerosis. Cell 145 (2011), 341–355.
82. Thieringer, R., Le Grand, C.B., Carbin, L., Cai, T.Q., Wong, B., Wright, S.D., Hermanowski-Vosatka, A., 11β-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J. Immunol. 167 (2001), 30–35.
83. Hermanowski-Vosatka, A., Balkovec, J.M., Cheng, K., Chen, H.Y., Hernandez, M., Koo, G.C., Le Grand, C.B., Li, Z., Metzger, J.M., Mundt, S.S., Noonan, H., Nunes, C.N., Olson, S.H., Pikounis, B., Ren, N., Robertson, N., Schaeffer, J.M., Shah, K., Springer, M.S., Strack, A.M., Strowski, M., Wu, K., Wu, T., Xiao, J., Zhang, B.B., Wright, S.D., Thieringer, R., 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 202 (2005), 517–527.
84. Luo, M.J., Thieringer, R., Springer, M.S., Wright, S.D., Hermanowski-Vosatka, A., Plump, A., Balkovec, J.M., Cheng, K., Ding, G.J., Kawka, D.W., Koo, G.C., Grand, C.B., Luo, Q., Maletic, M.M., Malkowitz, L., Shah, K., Singer, I., Waddell, S.T., Wu, K.K., Yuan, J., Zhu, J., Stepaniants, S., Yang, X., Lum, P.Y., Wang, I.M., 11β-HSD1 inhibition reduces atherosclerosis in mice by altering proinflammatory gene expression in the vasculature. Physiol. Genomics 45 (2013), 47–57.
85. Kipari, T., Hadoke, P.W., Iqbal, J., Man, T.Y., Miller, E., Coutinho, A.E., Zhang, Z., Sullivan, K.M., Mitic, T., Livingstone, D.E., Schrecker, C., Samuel, K., White, C.I., Bouhlel, M.A., Chinetti-Gbaguidi, G., Staels, B., Andrew, R., Walker, B.R., Savill, J.S., Chapman, K.E., Seckl, J.R., 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis. FASEB J. 27 (2013), 1519–1531.
86. Malatkova, P., Wsol, V., Carbonyl reduction pathways in drug metabolism. Drug Metab. Rev. 46 (2014), 96–123.
87. Hoffmann, F., Maser, E., Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab. Rev. 39 (2007), 87–144.
88. Stambergova, H., Skarydova, L., Dunford, J.E., Wsol, V., Biochemical properties of human dehydrogenase/reductase (SDR family) member 7. Chem. Biol. Interact. 207 (2014), 52–57.
89. Maser, E., Netter, K.J., Purification and properties of a metyrapone-reducing enzyme from mouse liver microsomes—this ketone is reduced by an aldehyde reductase. Biochem. Pharmacol. 38 (1989), 3049–3054.
90. Maser, E., Bannenberg, G., 11β-Hydroxysteroid dehydrogenase mediates reductive metabolism of xenobiotic carbonyl compounds. Biochem. Pharmacol. 47 (1994), 1805–1812.
91. Oppermann, U.C., Netter, K.J., Maser, E., Cloning and primary structure of murine 11β-hydroxysteroid dehydrogenase/microsomal carbonyl reductase. Eur. J. Biochem. 227 (1995), 202–208.
92. Hult, M., Nobel, C.S., Abrahmsen, L., Nicoll-Griffith, D.A., Jornvall, H., Oppermann, U.C., Novel enzymological profiles of human 11β-hydroxysteroid dehydrogenase type 1. Chem. Biol. Interact. 130–132 (2001), 805–814.
93. Wsol, V., Szotakova, B., Skalova, L., Maser, E., Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11β-hydroxysteroid dehydrogenase type 1. Chem. Biol. Interact. 143–144 (2003), 459–468.
94. Wsol, V., Szotakova, B., Skalova, L., Maser, E., The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11β-hydroxysteroid dehydrogenase type 1. Toxicology 197 (2004), 253–261.
95. Maser, E., Friebertshauser, J., Volker, B., Purification characterization and NNK carbonyl reductase activities of 11β-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. Chem. Biol. Interact. 143–144 (2003), 435–448.
96. Maser, E., Stinner, B., Atalla, A., Carbonyl reduction of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by cytosolic enzymes in human liver and lung. Cancer Lett. 148 (2000), 135–144.
97. Kenneke, J.F., Mazur, C.S., Ritger, S.E., Sack, T.J., Mechanistic investigation of the noncytochrome P450-mediated metabolism of triadimefon to triadimenol in hepatic microsomes. Chem. Res. Toxicol. 21 (2008), 1997–2004.
98. Meyer, A., Vuorinen, A., Zielinska, A.E., Da Cunha, T., Strajhar, P., Lavery, G.G., Schuster, D., Odermatt, A., Carbonyl reduction of triadimefon by human and rodent 11β-hydroxysteroid dehydrogenase 1. Biochem. Pharmacol. 85 (2013), 1370–1378.
99. Meyer, A., Vuorinen, A., Zielinska, A.E., Strajhar, P., Lavery, G.G., Schuster, D., Odermatt, A., Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1. Drug Metab. Dispos. 41 (2013), 1641–1648.
100. Skarydova, L., Tomanova, R., Havlikova, L., Stambergova, H., Solich, P., Wsol, V., Deeper insight into the reducing biotransformation of bupropion in the human liver. Drug Metab. Pharmacokinet. 29 (2014), 177–184.
101. Paillet-Loilier, M., Cesbron, A., Le Boisselier, R., Bourgine, J., Debruyne, D., Emerging drugs of abuse: current perspectives on substituted cathinones. Subst. Abuse Rehabil. 5 (2014), 37–52.
102. Nishihara, M., Takahashi, J., Kondo, T., Mouri, K., Asahi, S., Main metabolic pathways of TAK-802, a novel drug candidate for voiding dysfunction, in humans: the involvement of carbonyl reduction by 11β-hydroxysteroid dehydrogenase 1. Drug Res. (Stuttg.), 2013.